Project documents | Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067] | Guidance | NICE

Documents

A list of downloadable documents created during development.

Appeal

Appeal
Myeloma UK/Myeloma Society : Appeal letter ^{MSWord 44 KB} 23 September 2024
Sanofi : Appeal letter ^{MSWord 76 KB} 23 September 2024
Myeloma UK/Myeloma Society : Final scrutiny letter ^{MSWord 69 KB} 23 September 2024
Sanofi : Final scrutiny letter ^{MSWord 76 KB} 23 September 2024
Myeloma UK/Myeloma Society : Scrutiny letter ^{MSWord 74 KB} 23 September 2024
Sanofi : Scrutiny letter ^{MSWord 49 KB} 23 September 2024
Appeal decision ^{MSWord 92 KB} 12 November 2024

Final draft guidance

Final draft guidance
Final draft guidance ^{PDF 217 KB} 20 June 2024
Public committee slides ^{PDF 1.08 MB} 20 June 2024
Equality impact assessment (downloadable version) ^{PDF 129 KB} 20 June 2024

Draft guidance

Draft guidance
Appraisal consultation document (PDF version) ^{PDF 257 KB} 09 February 2024
Committee papers ^{PDF 17.83 MB} 09 February 2024
Public committee slides ^{PowerPoint 967 KB} 09 February 2024
Appraisal consultation document (online commenting)
Equality impact assessment (PDF Version) ^{PDF 148 KB} 09 February 2024

Committee meetings

Committee meeting: 1
Supporting documentation Register of interests ^{PDF 172 KB} 09 February 2024
Committee meeting: 2
Topic Register of Interest ^{PDF 159 KB} 20 March 2024

Invitation to participate

Final scope ^{PDF 196 KB} 03 February 2023
Final stakeholder list ^{PDF 167 KB} 03 February 2023
NICE's response to comments on the draft scope and provisional stakeholder list ^{PDF 257 KB} 03 February 2023
Equality impact assessment (Scoping) ^{PDF 125 KB} 03 February 2023